A Phase 2 interventional study of GLYC-101 Gel (0.1%) and GLYC-101 Gel (1.0%) in Wounds, sponsored by TR Therapeutics. Completed at 1 site in United States. Open to participants aged 25 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-10-28.
Sponsored by TR Therapeutics · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objectives of this study are to evaluate safety and efficacy of topically applied Glucoprime gel (GLYC-101, 0.1% and GLYC-101, 1.0%) in promoting wound healing in cosmetic surgery patients undergoing Carbon Dioxide Laser Skin Resurfacing (CO2 LSR) of the lower eyelids. The study will observe the effects of the topical agent over the course of 1 month following the initial treatment.
2,218 studies on the registry are indexed under Wounds and Injuries; 441 are open to participants now.
This study's enrollment of 26 is below the median of 70 across 1,424 interventional studies indexed under Wounds and Injuries.
Browse Wounds and Injuries studies →TR Therapeutics is the lead sponsor of 4 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GLYC-101 Gel, 0.1% on one eyelid and Placebo Gel on the other eyelid
Drug: GLYC-101 Gel (0.1%) · Drug: GLYC-101 Placebo
GLYC-101 Gel, 1.0% on one eyelid and Placebo Gel on the other eyelid
Drug: GLYC-101 Gel (1.0%) · Drug: GLYC-101 Placebo
GLYC-101 Gel, 0.1% on one eyelid and GLYC-101 Gel, 1.0% on the other eyelid
Drug: GLYC-101 Gel (0.1%) · Drug: GLYC-101 Gel (1.0%)
Topical administration to the laser-ablated area on days 1 (day of laser ablation), 2, 3, 4, and 5.
Topical administration to the laser-ablated area on days 1 (day of laser ablation), 2, 3, 4, and 5.
Topical administration to the laser-ablated area on days 1 (day of laser ablation), 2, 3, 4, and 5.
Time to Complete Wound Closure (Epithelialization)
Subjects were evaluated daily from the time of the laser procedure and initial application of test article until the subject's wounds reached 100% epithelialization. Efficacy was assessed based on the time to complete epithelialization in terms of the number of days from Day 1 (day of laser ablation) to the day on which complete epithelialization was observed.
Time frame: Over the course of 1 month following the initial treatment.
Cosmesis/11-point Likert Scale
The cosmetic effect on each lower eyelid using an 11-point Likert Scale (0 = not healed and 10 = healed).
Time frame: At 1 month following the initial treatment.
Recruitment started in October 2008 and ended in 2009 at a single site, Clinical Testing Center of Beverly Hills, Beverly Hills, California, United States, 90210.
| Milestone | GLYC-101 Gel, 0.1% on One Eyelid & Placebo on the Other Eyelid | GLYC-101 Gel, 1.0% on One Eyelid & Placebo on the Other Eyelid | GLYC-101 Gel 0.1% on 1 Eyelid & GLYC-101 Gel 1.0% on the Other |
|---|---|---|---|
| Started | 9 | 8 | 9 |
| Completed | 9 | 8 | 9 |
| Not completed | 0 | 0 | 0 |
Subjects were evaluated daily from the time of the laser procedure and initial application of test article until the subject's wounds reached 100% epithelialization. Efficacy was assessed based on the time to complete epithelialization in terms of the number of days from Day 1 (day of laser ablation) to the day on which complete epithelialization was observed.
| days | All Treatments GLYC-101 Gel, 0.1% | All Treatments GLYC-101 Gel, 1.0% | All Treatments Placebo |
|---|---|---|---|
| Time to Complete Wound Closure (Epithelialization) | 10.9 ± 5.17 | 13.1 ± 8.31 | 16.3 ± 9.93 |
The cosmetic effect on each lower eyelid using an 11-point Likert Scale (0 = not healed and 10 = healed).
| scores on a scale | All Treatments GLYC-101 Gel, 0.1% | All Treatments GLYC-101 Gel, 1.0% | All Treatments Placebo |
|---|---|---|---|
| Cosmesis/11-point Likert Scale | 8.9 ± 1.28 | 8.6 ± 1.17 | 8.5 ± 1.50 |
Collected over Adverse Events (AEs) were collected over the course of 1 month.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| GLYC-101 Gel, 0.1% on One Eyelid & Placebo on the Other Eyelid | — | 0/9 (0%) | 9/9 (100%) |
| GLYC-101 Gel, 1.0% on One Eyelid & Placebo on the Other Eyelid | — | 0/8 (0%) | 8/8 (100%) |
| GLYC-101 Gel 0.1% on 1 Eyelid & GLYC-101 Gel 1.0% on the Other | — | 1/9 (11.1%) | 9/9 (100%) |
| Event | GLYC-101 Gel, 0.1% on One Eyelid & Placebo on the Other Eyelid | GLYC-101 Gel, 1.0% on One Eyelid & Placebo on the Other Eyelid | GLYC-101 Gel 0.1% on 1 Eyelid & GLYC-101 Gel 1.0% on the Other |
|---|---|---|---|
| HIV test positiveInvestigations | 0/9 | 0/8 | 1/9 |
| Event | GLYC-101 Gel, 0.1% on One Eyelid & Placebo on the Other Eyelid | GLYC-101 Gel, 1.0% on One Eyelid & Placebo on the Other Eyelid | GLYC-101 Gel 0.1% on 1 Eyelid & GLYC-101 Gel 1.0% on the Other |
|---|---|---|---|
| Application site painGeneral disorders | 9/9 | 8/8 | 9/9 |
| Procedural painInjury, poisoning and procedural complications | 6/9 | 5/8 | 6/9 |
| Eye pruritusEye disorders | 4/9 | 3/8 | 6/9 |
| Impaired healingGeneral disorders | 2/9 | 1/8 | 1/9 |
| Chemical eye injuryInjury, poisoning and procedural complications | 0/9 | 1/8 | 0/9 |
| ConjunctivitisEye disorders | 0/9 | 1/8 | 0/9 |
| NauseaGastrointestinal disorders | 1/9 | 1/8 | 0/9 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 0/9 | 1/8 | 0/9 |
| VomitingGastrointestinal disorders | 1/9 | 0/8 | 0/9 |
| HeadacheNervous system disorders | 0/9 | 0/8 | 1/9 |
| Age, Categorical(Participants) | GLYC-101 Gel, 0.1% on One Eyelid & Placebo on the Other Eyelid | GLYC-101 Gel, 1.0% on One Eyelid & Placebo on the Other Eyelid | GLYC-101 Gel 0.1% on 1 Eyelid & GLYC-101 Gel 1.0% on the Other | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 9 | 7 | 8 | 24 |
| >=65 years | 0 | 1 | 1 | 2 |
| Age, Continuous(years) | GLYC-101 Gel, 0.1% on One Eyelid & Placebo on the Other Eyelid | GLYC-101 Gel, 1.0% on One Eyelid & Placebo on the Other Eyelid | GLYC-101 Gel 0.1% on 1 Eyelid & GLYC-101 Gel 1.0% on the Other | Total |
|---|---|---|---|---|
| Mean | 53.1 ± 7.98 | 46.4 ± 12.83 | 53.3 ± 9.41 | 51.1 ± 10.25 |
| Sex: Female, Male(Participants) | GLYC-101 Gel, 0.1% on One Eyelid & Placebo on the Other Eyelid | GLYC-101 Gel, 1.0% on One Eyelid & Placebo on the Other Eyelid | GLYC-101 Gel 0.1% on 1 Eyelid & GLYC-101 Gel 1.0% on the Other | Total |
|---|---|---|---|---|
| Female | 8 | 8 | 6 | 22 |
| Male | 1 | 0 | 3 | 4 |
| Region of Enrollment(participants) | GLYC-101 Gel, 0.1% on One Eyelid & Placebo on the Other Eyelid | GLYC-101 Gel, 1.0% on One Eyelid & Placebo on the Other Eyelid | GLYC-101 Gel 0.1% on 1 Eyelid & GLYC-101 Gel 1.0% on the Other | Total |
|---|---|---|---|---|
| United States | 9 | 8 | 9 | 26 |
The record gives a start of Oct 2008, a primary completion of Jan 2010 and a completion of Jan 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2011, 1 year 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Yeast .beta.-d-glucan